In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sichuan Kelun Pharmaceutical Co Ltd.

https://en.kelun.com/

Latest From Sichuan Kelun Pharmaceutical Co Ltd.

Chinese-Language Podcast: 聊聊七月生物制药热门话题

Join our China-based content team for this latest Chinese-language podcast episode discussing selected hot topics impacting the biopharma industry in China, including a homegrown COVID-19 antiviral approval, ADC deals and cross-strait tensions and their impact on the biotech sector. 

China Approvals

Dealmaking Quarterly Statistics, Q2 2022

During Q2, biopharma merger and acquisition value reached $25.4bn and drew in $27.3bn in potential deal value from alliances. Device company M&A values reached $2.7bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $534.3m.

Commercial Deals

Deal Watch: Cidara Licenses US Rights To Antifungal Under FDA Review To Melinta

Cidara gets $30m up front for US rights to the weekly echinocandin candidate for candidemia and invasive candidiasis. Takeda walks away from oncolytic virus candidate licensed from Turnstone.

Deal Watch Business Strategies

Chinese Biotechs Partner Up 18.2-Targeting ADCs Amid Intense Domestic Competition

Following rapid R&D growth in the area, China now has roughly 40 drug candidates targeting Claudin 18.2 across various modalities including monoclonal antibodies, antibody-drug conjugates and bispecific antibodies, with a number of contenders now striking international licensing-out deals in a bid to get ahead of rivals.

China Deals
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
    • Nutraceuticals
    • Vaccines
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
      • Antibodies
    • Drug Discovery Technologies
      • Molecular Diversity
        • Natural Products
  • Other Names / Subsidiaries
    • Guangxi Kelun Pharmaceutical Co Ltd
    • Hunan Kelun Pharmaceutical Co Ltd
    • Hubei Kelun Pharmaceutical Co Ltd
    • Kelun Pharmaceutical Group
    • KLUS Pharma Inc
    • Shandong Kelun Pharmaceutical Co Ltd
    • Sichuan Kelun Pharmaceutical Research Co Ltd
    • Suzhou Kelun Pharmaceutical Research Co Ltd
    • Sichuan Xindi Pharmaceutical Chemicals Co Ltd
UsernamePublicRestriction

Register